Final Exam Practice Test Bank for NR565
with 300+ Latest Practice Questions and
Correct Answers Graded A+
Chamberlain/ NR 565 Final Practice Test /
NR565 Final
Section 1: Pharmacokinetics & Pharmacodynamics
1. A patient with hepatic cirrhosis is prescribed a medication with high first-pass metabolism. The
provider should anticipate:
A) Decreased bioavailability requiring a lower dose
B) Increased bioavailability requiring a lower dose
C) No change in dosing
D) Increased renal excretion
Rationale: Liver disease reduces first-pass metabolism, leading to a higher proportion of the drug
reaching systemic circulation. Therefore, a lower dose is required to prevent toxicity.
2. The time required for the serum concentration of a drug to decrease by 50% is known as:
A) Onset of action
B) Half-life
C) Therapeutic index
D) Bioavailability
Rationale: Half-life (t½) is the definitive measure of the time it takes for the drug's plasma concentration
to fall by half.
3. A drug that acts as an agonist at a receptor will:
A) Block the receptor site
B) Produce a maximum biologic response
C) Have no effect on the cell
D) Require a higher dose to be effective
Rationale: Agonists bind to and activate receptors, mimicking the endogenous ligand to produce a
biological response.
4. The volume of plasma from which a drug is completely removed per unit of time is:
A) Bioavailability
B) First-pass effect
C) Clearance
,D) Steady state
Rationale: Clearance (Cl) is the measure of the body's efficiency in eliminating a drug, often described as
the volume of blood cleared of drug per minute.
5. An antagonist drug has what characteristic?
A) High intrinsic activity
B) Affinity for the receptor but no intrinsic activity
C) Low affinity but high efficacy
D) Binds only to plasma proteins
Rationale: Antagonists have receptor affinity (they bind) but lack intrinsic activity (they do not activate
the receptor), thus blocking the effect of agonists.
6. A medication with a narrow therapeutic index requires:
A) Infrequent monitoring
B) No dose adjustments
C) Close serum concentration monitoring
D) High protein binding
Rationale: A narrow therapeutic index means the margin between therapeutic and toxic doses is small,
necessitating therapeutic drug monitoring.
7. A patient is prescribed a weak acid drug. In an acidic environment (e.g., stomach), this drug will be:
A) Ionized and readily absorbed
B) Un-ionized and readily absorbed
C) Trapped in the stomach
D) Excreted rapidly
Rationale: Weak acids are non-ionized (lipid-soluble) in acidic environments, allowing them to cross cell
membranes easily and be absorbed.
8. The process by which a drug moves from the bloodstream into the site of action is termed:
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Rationale: Distribution describes the reversible transfer of a drug from the bloodstream into tissues and
the target site.
9. A drug with a high volume of distribution (Vd) indicates that the drug:
A) Is confined to the plasma
B) Is highly protein bound
C) Is extensively distributed into tissue
D) Has a short half-life
Rationale: A high Vd indicates the drug leaves the plasma and distributes widely into tissues and organs.
10. Phase I biotransformation reactions primarily involve:
A) Conjugation
B) Oxidation, reduction, and hydrolysis
C) Acetylation
,D) Glucuronidation
Rationale: Phase I reactions (CYP450 system) introduce or expose a functional group via oxidation,
reduction, or hydrolysis.
11. A patient’s liver enzymes are induced by rifampin. This will result in:
A) Decreased metabolism of other drugs
B) Increased metabolism of other drugs
C) Increased half-life of other drugs
D) Decreased renal clearance
Rationale: Enzyme induction increases the rate of metabolism, leading to decreased serum
concentrations of co-administered drugs that are substrates.
12. Grapefruit juice inhibits CYP3A4. Taking a statin with grapefruit juice will:
A) Increase the risk of toxicity
B) Decrease the risk of toxicity
C) Have no effect
D) Increase the efficacy
Rationale: Inhibition of CYP3A4 decreases metabolism of the statin, leading to higher serum levels and
increased risk of myopathy/rhabdomyolysis.
13. The term "steady state" refers to:
A) The peak concentration of the drug
B) The trough concentration
C) The rate of drug administration equals the rate of elimination
D) Complete clearance of the drug
Rationale: Steady state is achieved when the amount of drug entering the body equals the amount
being eliminated, resulting in consistent serum levels.
14. A patient is on a medication that is 90% protein bound. If a second highly protein-bound drug is
introduced, the first drug will:
A) Have an increased free fraction
B) Have a decreased free fraction
C) Maintain the same free fraction
D) Be excreted faster
Rationale: Competition for protein binding sites displaces the first drug, increasing its free (active)
fraction and potential effect/toxicity.
15. The therapeutic index (TI) is calculated by:
A) ED50 / TD50
B) TD50 / ED50
C) LD50 / ED50
D) ED50 / LD50
Rationale: TI = TD50 (toxic dose in 50%) divided by ED50 (effective dose in 50%). The higher the number,
the safer the drug.
16. An anticholinergic medication like atropine works by blocking:
A) Beta-1 receptors
, B) Muscarinic receptors
C) Nicotinic receptors
D) Alpha-1 receptors
Rationale: Atropine is a muscarinic antagonist, blocking parasympathetic effects.
17. Alpha-1 receptor stimulation results in:
A) Bronchodilation
B) Vasoconstriction
C) Decreased heart rate
D) Increased GI motility
Rationale: Alpha-1 receptors are located on vascular smooth muscle. Stimulation causes
vasoconstriction and increased peripheral resistance.
18. A patient on a beta-blocker develops bradycardia. Which receptor is primarily affected?
A) Alpha-1
B) Beta-1
C) Beta-2
D) Dopaminergic
Rationale: Beta-1 receptors are located in the heart. Blockade reduces heart rate and contractility.
19. Beta-2 receptor stimulation is responsible for:
A) Vasoconstriction
B) Increased heart rate
C) Bronchodilation
D) Glycogen synthesis
Rationale: Beta-2 receptors in the lungs cause bronchodilation. This is the mechanism of albuterol.
20. A direct-acting cholinergic agonist (e.g., pilocarpine) will cause:
A) Mydriasis
B) Miosis
C) Tachycardia
D) Dry mouth
Rationale: Direct-acting agonists stimulate muscarinic receptors in the eye, causing pupillary constriction
(miosis).
21. A patient has been on a glucocorticoid for 3 months. The APRN understands that abrupt cessation
may lead to:
A) Cushing’s syndrome
B) Adrenal crisis
C) Hyperglycemia
D) Hypertension
Rationale: Exogenous steroids suppress the HPA axis. Abrupt withdrawal prevents the adrenal glands
from producing cortisol, leading to adrenal insufficiency.
22. A 65-year-old patient has a creatinine clearance of 30 mL/min. For a renally excreted drug, the
provider should:
A) Increase the dose
with 300+ Latest Practice Questions and
Correct Answers Graded A+
Chamberlain/ NR 565 Final Practice Test /
NR565 Final
Section 1: Pharmacokinetics & Pharmacodynamics
1. A patient with hepatic cirrhosis is prescribed a medication with high first-pass metabolism. The
provider should anticipate:
A) Decreased bioavailability requiring a lower dose
B) Increased bioavailability requiring a lower dose
C) No change in dosing
D) Increased renal excretion
Rationale: Liver disease reduces first-pass metabolism, leading to a higher proportion of the drug
reaching systemic circulation. Therefore, a lower dose is required to prevent toxicity.
2. The time required for the serum concentration of a drug to decrease by 50% is known as:
A) Onset of action
B) Half-life
C) Therapeutic index
D) Bioavailability
Rationale: Half-life (t½) is the definitive measure of the time it takes for the drug's plasma concentration
to fall by half.
3. A drug that acts as an agonist at a receptor will:
A) Block the receptor site
B) Produce a maximum biologic response
C) Have no effect on the cell
D) Require a higher dose to be effective
Rationale: Agonists bind to and activate receptors, mimicking the endogenous ligand to produce a
biological response.
4. The volume of plasma from which a drug is completely removed per unit of time is:
A) Bioavailability
B) First-pass effect
C) Clearance
,D) Steady state
Rationale: Clearance (Cl) is the measure of the body's efficiency in eliminating a drug, often described as
the volume of blood cleared of drug per minute.
5. An antagonist drug has what characteristic?
A) High intrinsic activity
B) Affinity for the receptor but no intrinsic activity
C) Low affinity but high efficacy
D) Binds only to plasma proteins
Rationale: Antagonists have receptor affinity (they bind) but lack intrinsic activity (they do not activate
the receptor), thus blocking the effect of agonists.
6. A medication with a narrow therapeutic index requires:
A) Infrequent monitoring
B) No dose adjustments
C) Close serum concentration monitoring
D) High protein binding
Rationale: A narrow therapeutic index means the margin between therapeutic and toxic doses is small,
necessitating therapeutic drug monitoring.
7. A patient is prescribed a weak acid drug. In an acidic environment (e.g., stomach), this drug will be:
A) Ionized and readily absorbed
B) Un-ionized and readily absorbed
C) Trapped in the stomach
D) Excreted rapidly
Rationale: Weak acids are non-ionized (lipid-soluble) in acidic environments, allowing them to cross cell
membranes easily and be absorbed.
8. The process by which a drug moves from the bloodstream into the site of action is termed:
A) Absorption
B) Distribution
C) Metabolism
D) Excretion
Rationale: Distribution describes the reversible transfer of a drug from the bloodstream into tissues and
the target site.
9. A drug with a high volume of distribution (Vd) indicates that the drug:
A) Is confined to the plasma
B) Is highly protein bound
C) Is extensively distributed into tissue
D) Has a short half-life
Rationale: A high Vd indicates the drug leaves the plasma and distributes widely into tissues and organs.
10. Phase I biotransformation reactions primarily involve:
A) Conjugation
B) Oxidation, reduction, and hydrolysis
C) Acetylation
,D) Glucuronidation
Rationale: Phase I reactions (CYP450 system) introduce or expose a functional group via oxidation,
reduction, or hydrolysis.
11. A patient’s liver enzymes are induced by rifampin. This will result in:
A) Decreased metabolism of other drugs
B) Increased metabolism of other drugs
C) Increased half-life of other drugs
D) Decreased renal clearance
Rationale: Enzyme induction increases the rate of metabolism, leading to decreased serum
concentrations of co-administered drugs that are substrates.
12. Grapefruit juice inhibits CYP3A4. Taking a statin with grapefruit juice will:
A) Increase the risk of toxicity
B) Decrease the risk of toxicity
C) Have no effect
D) Increase the efficacy
Rationale: Inhibition of CYP3A4 decreases metabolism of the statin, leading to higher serum levels and
increased risk of myopathy/rhabdomyolysis.
13. The term "steady state" refers to:
A) The peak concentration of the drug
B) The trough concentration
C) The rate of drug administration equals the rate of elimination
D) Complete clearance of the drug
Rationale: Steady state is achieved when the amount of drug entering the body equals the amount
being eliminated, resulting in consistent serum levels.
14. A patient is on a medication that is 90% protein bound. If a second highly protein-bound drug is
introduced, the first drug will:
A) Have an increased free fraction
B) Have a decreased free fraction
C) Maintain the same free fraction
D) Be excreted faster
Rationale: Competition for protein binding sites displaces the first drug, increasing its free (active)
fraction and potential effect/toxicity.
15. The therapeutic index (TI) is calculated by:
A) ED50 / TD50
B) TD50 / ED50
C) LD50 / ED50
D) ED50 / LD50
Rationale: TI = TD50 (toxic dose in 50%) divided by ED50 (effective dose in 50%). The higher the number,
the safer the drug.
16. An anticholinergic medication like atropine works by blocking:
A) Beta-1 receptors
, B) Muscarinic receptors
C) Nicotinic receptors
D) Alpha-1 receptors
Rationale: Atropine is a muscarinic antagonist, blocking parasympathetic effects.
17. Alpha-1 receptor stimulation results in:
A) Bronchodilation
B) Vasoconstriction
C) Decreased heart rate
D) Increased GI motility
Rationale: Alpha-1 receptors are located on vascular smooth muscle. Stimulation causes
vasoconstriction and increased peripheral resistance.
18. A patient on a beta-blocker develops bradycardia. Which receptor is primarily affected?
A) Alpha-1
B) Beta-1
C) Beta-2
D) Dopaminergic
Rationale: Beta-1 receptors are located in the heart. Blockade reduces heart rate and contractility.
19. Beta-2 receptor stimulation is responsible for:
A) Vasoconstriction
B) Increased heart rate
C) Bronchodilation
D) Glycogen synthesis
Rationale: Beta-2 receptors in the lungs cause bronchodilation. This is the mechanism of albuterol.
20. A direct-acting cholinergic agonist (e.g., pilocarpine) will cause:
A) Mydriasis
B) Miosis
C) Tachycardia
D) Dry mouth
Rationale: Direct-acting agonists stimulate muscarinic receptors in the eye, causing pupillary constriction
(miosis).
21. A patient has been on a glucocorticoid for 3 months. The APRN understands that abrupt cessation
may lead to:
A) Cushing’s syndrome
B) Adrenal crisis
C) Hyperglycemia
D) Hypertension
Rationale: Exogenous steroids suppress the HPA axis. Abrupt withdrawal prevents the adrenal glands
from producing cortisol, leading to adrenal insufficiency.
22. A 65-year-old patient has a creatinine clearance of 30 mL/min. For a renally excreted drug, the
provider should:
A) Increase the dose
